InsidersTradesSigma
Egetis Therapeutics AB (publ) Stock: price and management transactions · Finland · FIN-FSA
Follow the Egetis Therapeutics AB (publ) share price and the full insider trade history of the company, a listed issuer based in Finland. Shares trade on FI FI, under the oversight of FIN-FSA. Operating in the Health Care sector, Egetis Therapeutics AB (publ) has published 23 insider filings. Market capitalisation: €2.7bn. The latest transaction was disclosed on 27 June 2026 (Sale). Among the most active insiders: Christian Sonesson. All data is accessible without an account.
23
Insider Decl.
0
Thresholds
€52,213
15 ops.
Buy Volume
€841,776
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Egetis Therapeutics AB (publ) Buy (bullish), based on 4 analysts. Average price target: SEK 11.90.
34Σ signal
Fundamental score
Ranked 24,440 of 25,451 companies
14.3
score / 100
Value15
Quality14
FCF yld-9.8%
Earn yld-12%
EV/EBITDA·
ROE-110%
Gross mgn20%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 27 June 2026
Declarations23 total
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
158,928 shares@ SEK 6.500.0033% mcap48.3% of flowAktieFI:csv-2095cc230f6097f680ca
264,880 shares0AktieFI:csv-175d73b1ea8853239cdb
Ideal exit: 5 Feb 2027 (T+270)
37,202 shares0AktieFI:csv-e9e8616ad9038e8953be
Ideal exit: 5 Feb 2027 (T+270)
264,880 shares0AktieFI:csv-1ef0079ec6f2384808c5
Ideal exit: 5 Feb 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
158,928 shares@ SEK 6.500.0039% mcap93.6% of flowAktieFI:csv-f87ec71e64a442ce7e24
529,761 shares0AktieFI:csv-841ca189a7c635e1917d
Ideal exit: 5 Feb 2027 (T+270)
286,071 shares@ SEK 6.500.0070% mcap100.0% of flowAktieFI:csv-080acb505ed56ada1bf4
529,761 shares0AktieFI:A003Y632-1
Ideal exit: 5 Feb 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
264,880 shares0AktieFI:A003Y653-1
Ideal exit: 5 Feb 2027 (T+270)
264,880 shares0AktieFI:csv-5062421e5700a2577d48
Ideal exit: 5 Feb 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
264,880 shares@ SEK 6.500.0064% mcap94.6% of flowAktieFI:csv-4f6c60d76c6f9c961f8e
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
264,880 shares0AktieFI:A003Y615-1
Ideal exit: 5 Feb 2027 (T+270)
265,620 shares0AktieFI:csv-c81607ca7a4dc540e585
Ideal exit: 5 Feb 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
119,529 shares@ SEK 6.500.0029% mcap46.5% of flowAktieFI:csv-6bcea8f583b1cb375000
264,880 shares0AktieFI:csv-20298035c5d4dc97dbf5
Ideal exit: 5 Feb 2027 (T+270)
153,631 shares@ SEK 6.500.0037% mcap44.8% of flowAktieFI:csv-fd45067293b119868f0a
153,631 shares@ SEK 6.500.0043% mcap81.3% of flowAktieFI:A003Y582-1
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
119,529 shares@ €0.59480.0034% mcap86.9% of flowAktieFI:A003Y593-1
60,000 shares@ €0.35090.0010% mcap18.7% of flowAktieFI:A003U276-2
Ideal exit: 23 Aug 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
25,000 shares@ €0.43030.0005% mcap13.1% of flowAktieFI:A003U284-1
Ideal exit: 25 Aug 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
15,000 shares@ €0.43340.0003% mcap100.0% of flowAktieFI:A003U244-2
Ideal exit: 24 Aug 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
25,000 shares@ €0.35720.0004% mcap100.0% of flowAktieFI:A003U240-1
Ideal exit: 23 Aug 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
13,460 shares@ €0.36940.0002% mcap100.0% of flowAktieFI:A003P637-1
Ideal exit: 2 Mar 2026 (T+270)
23 of 23 declarations
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ) is a Swedish biopharmaceutical company focused on developing treatments for rare diseases. It is listed on the Stockholm Stock Exchange (XSTO).
